Inactive Instrument

Standard BioTools Inc.

SLGC

US83444K1051

Biotechnology & Medical Research

SomaLogic Inc. Provides Revenue Guidance for the Full Year 2022

August 16, 2022 at 02:01 am IST

SomaLogic Inc. provided revenue guidance for the full year 2022. For the year, the company expects revenue to be in the range of $80.0 million to $90.0 million.

Latest news about Standard BioTools Inc.

Standard BioTools Inc.(NasdaqGM:SLGC) dropped from S&P Global BMI Index	10/01	CI
Standard BioTools Inc.(NasdaqGM:SLGC) dropped from S&P TMI Index	10/01	CI
Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023	08/01	CI
Declaration of Voting Results by SomaLogic Inc	06/01	CI
Declaration of Voting Results by SomaLogic Inc	06/01	CI
Declaration of Voting Results by SomaLogic Inc	06/01	CI
Declaration of Voting Results by SomaLogic Inc	06/01	CI
Declaration of Voting Results by SomaLogic Inc	06/01	CI
Standard BioTools Says Merger With SomaLogic Completed	05/01	MT
SomaLogic, Standard BioTools Receive Shareholder Approvals for Pending Merger	05/01	MT
SomaLogic, Inc.(NasdaqGM:SLGC) dropped from NASDAQ Composite Index	05/01	CI
Madryn Asset Addresses SomaLogic?s Failure to Obtain Requisite Shareholder Support for the Proposed Merger with Standard BioTools	05/01	CI
Madryn Asset Management, LP Sends an Email to Stockholders in Connection with Somalogic, Inc.?s Special Meeting of Stockholders	04/01	CI
Madryn Asset Management Sent a Letter to the Delaware Court of Chancery	04/01	CI
Madryn Asset Provides Information to the Shareholders	04/01	CI
Egan-Jones Recommends SomaLogic Shareholders Vote Against Proposed Merger with Standard BioTools	03/01	CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc	03/01	CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc	03/01	CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc	03/01	CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc	03/01	CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc	03/01	CI
SomaLogic Sends an Open Letter to Shareholders	02/01	CI
SomaLogic Sends an Open Letter to Shareholders	02/01	CI
SomaLogic Sends an Open Letter to Shareholders	02/01	CI
SomaLogic Sends an Open Letter to Shareholders	02/01	CI

SomaLogic, Inc. is a commercial-stage proteomics company. The Company has built an integrated proteomics platform, which offers throughput proteomics analysis with broad proteome coverage. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. It offers SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. Its products include SomaScan Assay, SomaScan Certified Sites, SomaSignal Tests and SOMAmer Reagents. SomaScan Assay is utilized for Research Use Only (RUO) applications. Its SomaScan Assay measures approximately 7,000 protein target measurements in a single sample. Its SOMAmer reagents are proprietary modified aptamers, which are short, synthetic single-stranded DNA (ssDNA) sequences developed to bind specific protein targets with high affinity and specificity across the proteome.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+43.36%	5.46TCr
IQVIA HOLDINGS INC.	-5.31%	3.99TCr
LONZA GROUP AG	+37.52%	3.88TCr
ICON PUBLIC LIMITED COMPANY	+14.75%	2.69TCr
CELLTRION, INC.	-12.56%	2.62TCr
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	1.88TCr
BIO-TECHNE CORPORATION	+0.04%	1.22TCr
UNITED THERAPEUTICS CORPORATION	+25.12%	1.22TCr
MEDPACE HOLDINGS, INC.	+26.04%	1.19TCr

Other Biotechnology & Medical Research

Standard BioTools Inc.

Equities

SLGC

US83444K1051

Biotechnology & Medical Research

SomaLogic Inc. Provides Revenue Guidance for the Full Year 2022

Latest news about Standard BioTools Inc.

Chart Standard BioTools Inc.

Company Profile

Sector Other Biotechnology & Medical Research